• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

尿激酶受体的蛋白水解切割可替代激动剂诱导的趋化作用。

Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.

作者信息

Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F, Fazioli F

机构信息

Department of Biology and Biotechnology, San Raffaele Scientific Institute, Milano, Italy.

出版信息

EMBO J. 1996 Apr 1;15(7):1572-82.

PMID:8612581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC450067/
Abstract

Physiological concentrations of urokinase plasminogen activator (uPA) stimulated a chemotactic response in human monocytic THP-1 through binding to the urokinase receptor (uPAR). The effect did not require the protease moiety of uPA, as stimulation was achieved also with the N-terminal fragment (ATF), while the 33 kDa low molecular weight uPA was ineffective. Co-immunoprecipitation experiments showed association of uPAR with intracellular kinase(s), as demonstrated by in vitro kinase assays. Use of specific antibodies identified p56/p59hck as a kinase associated with uPAR in THP-1 cell extracts. Upon addition of ATF, p56/p59hck activity was stimulated within 2 min and returned to normal after 30 min. Since uPAR lacks an intracellular domain capable of interacting with intracellular kinase, activation of p56/p59hck must require a transmembrane adaptor. Evidence for this was strongly supported by the finding that a soluble form of uPAR (suPAR) was capable of inducing chemotaxis not only in THP-1 cells but also in cells lacking endogenous uPAR (IC50, 5 pM). However, activity of suPAR require chymotrypsin cleavage between the N-terminal domain D1 and D2 + D3. Chymotrypsin-cleaved suPAR also induced activation of p56/p59hck in THP-1 cells, with a time course comparable with ATF. Our data show that uPA-induced signal transduction takes place via uPAR, involves activation of intracellular tyrosine kinase(s) and requires an as yet undefined adaptor capable of connecting the extracellular ligand binding uPAR to intracellular transducer(s).

摘要

尿激酶型纤溶酶原激活剂(uPA)的生理浓度通过与尿激酶受体(uPAR)结合,刺激人单核细胞THP-1产生趋化反应。该效应不需要uPA的蛋白酶部分,因为N端片段(ATF)也能实现刺激,而33 kDa的低分子量uPA则无效。免疫共沉淀实验表明uPAR与细胞内激酶相关,体外激酶测定证实了这一点。使用特异性抗体鉴定出p56/p59hck是THP-1细胞提取物中与uPAR相关的激酶。加入ATF后,p56/p59hck活性在2分钟内被激活,并在30分钟后恢复正常。由于uPAR缺乏能够与细胞内激酶相互作用的细胞内结构域,p56/p59hck的激活必定需要一个跨膜衔接子。可溶性形式的uPAR(suPAR)不仅能够在THP-1细胞中诱导趋化,而且能够在缺乏内源性uPAR的细胞中诱导趋化(IC50,5 pM),这一发现有力地支持了这一点。然而,suPAR的活性需要在N端结构域D1和D2 + D3之间进行胰凝乳蛋白酶切割。经胰凝乳蛋白酶切割的suPAR也能在THP-1细胞中诱导p56/p59hck的激活,其时间进程与ATF相当。我们的数据表明,uPA诱导的信号转导通过uPAR发生,涉及细胞内酪氨酸激酶的激活,并且需要一个尚未明确的衔接子,该衔接子能够将结合细胞外配体的uPAR与细胞内转导器连接起来。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/a93191131728/emboj00007-0110-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/380bd2099e26/emboj00007-0106-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/7c633f1b6de8/emboj00007-0106-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/107a8ba82958/emboj00007-0107-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/fe001a7df25e/emboj00007-0108-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/0bac6a922c84/emboj00007-0109-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/d3ac8c6f542a/emboj00007-0109-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/a93191131728/emboj00007-0110-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/380bd2099e26/emboj00007-0106-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/7c633f1b6de8/emboj00007-0106-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/107a8ba82958/emboj00007-0107-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/fe001a7df25e/emboj00007-0108-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/0bac6a922c84/emboj00007-0109-a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/d3ac8c6f542a/emboj00007-0109-b.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9187/450067/a93191131728/emboj00007-0110-a.jpg

相似文献

1
Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.尿激酶受体的蛋白水解切割可替代激动剂诱导的趋化作用。
EMBO J. 1996 Apr 1;15(7):1572-82.
2
Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.通过与尿激酶型纤溶酶原激活剂相互作用,尿激酶特异性表面受体的高表达得以维持。
Mol Carcinog. 2007 Mar;46(3):165-75. doi: 10.1002/mc.20249.
3
Urokinase receptor-dependent and -independent p56/59(hck) activation state is a molecular switch between myelomonocytic cell motility and adherence.尿激酶受体依赖性和非依赖性p56/59(hck)激活状态是骨髓单核细胞运动性和黏附性之间的分子开关。
EMBO J. 1999 Jun 1;18(11):3013-23. doi: 10.1093/emboj/18.11.3013.
4
Cyclo19,31[D-Cys19]-uPA19-31 is a potent competitive antagonist of the interaction of urokinase-type plasminogen activator with its receptor (CD87).环[19,31][D-半胱氨酸19]-尿激酶型纤溶酶原激活剂19-31是尿激酶型纤溶酶原激活剂与其受体(CD87)相互作用的强效竞争性拮抗剂。
Biol Chem. 2001 Aug;382(8):1197-205. doi: 10.1515/BC.2001.150.
5
A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity.人尿激酶受体的一个尿激酶敏感区域负责其趋化活性。
EMBO J. 1997 Dec 15;16(24):7279-86. doi: 10.1093/emboj/16.24.7279.
6
Receptor-mediated regulation of plasminogen activator function: plasminogen activation by two directly membrane-anchored forms of urokinase.受体介导的纤溶酶原激活物功能调节:两种直接膜锚定形式的尿激酶对纤溶酶原的激活作用
J Pept Sci. 2000 Sep;6(9):432-9. doi: 10.1002/1099-1387(200009)6:9<432::AID-PSC279>3.0.CO;2-Q.
7
Discrimination of different forms of the murine urokinase plasminogen activator receptor on the cell surface using monoclonal antibodies.利用单克隆抗体鉴别细胞表面小鼠尿激酶型纤溶酶原激活物受体的不同形式
J Immunol Methods. 2008 Nov 30;339(1):55-65. doi: 10.1016/j.jim.2008.08.002. Epub 2008 Aug 30.
8
Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck).可溶性尿激酶受体促进细胞黏附,并且激活p56/59(hck)需要酪氨酸92。
Biochem Biophys Res Commun. 2000 Nov 19;278(2):440-6. doi: 10.1006/bbrc.2000.3818.
9
Urokinase-type plasminogen activator binding to its receptor stimulates tumor cell migration by enhancing integrin-mediated signal transduction.尿激酶型纤溶酶原激活剂与其受体结合,通过增强整合素介导的信号转导来刺激肿瘤细胞迁移。
Exp Cell Res. 1999 Jul 10;250(1):231-40. doi: 10.1006/excr.1999.4510.
10
Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.尿激酶型纤溶酶原激活物受体(uPAR)在血液和骨髓细胞上的结构、功能及表达
Stem Cells. 1997;15(6):398-408. doi: 10.1002/stem.150398.

引用本文的文献

1
Prognostic significance of the urokinase plasminogen activator system in tissue and serum of dogs with appendicular osteosarcoma.尿激酶纤溶酶原激活系统在犬附肢骨肉瘤组织和血清中的预后意义。
PLoS One. 2022 Sep 29;17(9):e0273811. doi: 10.1371/journal.pone.0273811. eCollection 2022.
2
suPAR: An Inflammatory Mediator for Kidneys.可溶性尿激酶型纤溶酶原激活物受体:肾脏的一种炎症介质。
Kidney Dis (Basel). 2022 Jun 8;8(4):265-274. doi: 10.1159/000524965. eCollection 2022 Jul.
3
suPAR to Risk-Stratify Patients With Malaria.可溶性尿激酶型纤溶酶原激活物受体(suPAR)用于疟疾患者的风险分层。

本文引用的文献

1
Biology and biochemistry of proteinases in tumor invasion.肿瘤侵袭中蛋白酶的生物学与生物化学
Physiol Rev. 1993 Jan;73(1):161-95. doi: 10.1152/physrev.1993.73.1.161.
2
Distribution and lateral mobility of the urokinase-receptor complex at the cell surface.
J Histochem Cytochem. 1993 Sep;41(9):1291-301. doi: 10.1177/41.9.8394852.
3
Interaction of urokinase-type plasminogenactivator (u-PA) with its cellular receptor (u-PAR) induces phosphorylation on tyrosine of a 38 kDa protein.尿激酶型纤溶酶原激活剂(u-PA)与其细胞受体(u-PAR)的相互作用会诱导一种38 kDa蛋白质的酪氨酸磷酸化。
Front Immunol. 2022 Jun 10;13:931321. doi: 10.3389/fimmu.2022.931321. eCollection 2022.
4
Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a Biomarker of Systemic Chronic Inflammation.可溶性尿激酶型纤溶酶原激活物受体(suPAR)作为全身性慢性炎症的生物标志物。
Front Immunol. 2021 Dec 2;12:780641. doi: 10.3389/fimmu.2021.780641. eCollection 2021.
5
The Urokinase Receptor (uPAR) as a "Trojan Horse" in Targeted Cancer Therapy: Challenges and Opportunities.尿激酶受体(uPAR)作为靶向癌症治疗中的“特洛伊木马”:挑战与机遇
Cancers (Basel). 2021 Oct 27;13(21):5376. doi: 10.3390/cancers13215376.
6
Plasminogen activator receptor assemblies in cell signaling, innate immunity, and inflammation.纤溶酶原激活物受体在细胞信号转导、固有免疫和炎症中的组装。
Am J Physiol Cell Physiol. 2021 Oct 1;321(4):C721-C734. doi: 10.1152/ajpcell.00269.2021. Epub 2021 Aug 18.
7
Multifaced Roles of the Urokinase System in the Regulation of Stem Cell Niches.尿激酶系统在干细胞微环境调节中的多面作用
Acta Naturae. 2018 Oct-Dec;10(4):19-32.
8
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.尿激酶型纤溶酶原激活剂(uPA)及其受体(uPAR)的多方面作用:诊断、预后及治疗应用
Front Oncol. 2018 Feb 12;8:24. doi: 10.3389/fonc.2018.00024. eCollection 2018.
9
Soluble Urokinase Receptor Is Released Selectively by Glioblastoma Cells That Express Epidermal Growth Factor Receptor Variant III and Promotes Tumor Cell Migration and Invasion.可溶性尿激酶受体由表达表皮生长因子受体变异体III的胶质母细胞瘤细胞选择性释放,并促进肿瘤细胞迁移和侵袭。
J Biol Chem. 2015 Jun 12;290(24):14798-809. doi: 10.1074/jbc.M115.637488. Epub 2015 Apr 2.
10
Role of formic receptors in soluble urokinase receptor-induced human vascular smooth muscle migration.甲酸受体在可溶性尿激酶受体诱导的人血管平滑肌迁移中的作用。
J Surg Res. 2015 May 15;195(2):396-405. doi: 10.1016/j.jss.2015.02.003. Epub 2015 Feb 12.
FEBS Lett. 1993 May 3;322(1):37-40. doi: 10.1016/0014-5793(93)81106-a.
4
Urokinase-urokinase receptor interaction: non-mitogenic signal transduction in human epidermal cells.尿激酶-尿激酶受体相互作用:人表皮细胞中的非促有丝分裂信号转导
Biochem Biophys Res Commun. 1993 Jan 29;190(2):347-52. doi: 10.1006/bbrc.1993.1054.
5
The urokinase receptor is required for human monocyte chemotaxis in vitro.体外人类单核细胞趋化性需要尿激酶受体。
J Clin Invest. 1994 Apr;93(4):1380-7. doi: 10.1172/JCI117114.
6
Urokinase-type plasminogen activator and its receptor: new targets for anti-metastatic therapy?尿激酶型纤溶酶原激活剂及其受体:抗转移治疗的新靶点?
Trends Pharmacol Sci. 1994 Jan;15(1):25-9. doi: 10.1016/0165-6147(94)90130-9.
7
Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor.用8-苯胺基-1-萘磺酸盐探测尿激酶型纤溶酶原激活剂与其受体之间的配体相互作用。仅在完整受体上暴露疏水结合位点的证据。
Biochemistry. 1994 Aug 2;33(30):8991-7. doi: 10.1021/bi00196a017.
8
Protease nexin-1-urokinase complexes are internalized and degraded through a mechanism that requires both urokinase receptor and alpha 2-macroglobulin receptor.蛋白酶连接素-1-尿激酶复合物通过一种既需要尿激酶受体又需要α2-巨球蛋白受体的机制被内化并降解。
J Biol Chem. 1994 Jul 8;269(27):17886-92.
9
A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors.侵袭性移植的人源和鼠源肿瘤中尿激酶型纤溶酶原激活物受体的裂解形式。
Int J Cancer. 1994 Sep 15;58(6):877-81. doi: 10.1002/ijc.2910580622.
10
Biological activation of pro-HGF (hepatocyte growth factor) by urokinase is controlled by a stoichiometric reaction.
J Biol Chem. 1995 Jan 13;270(2):603-11. doi: 10.1074/jbc.270.2.603.